Thinking of joining a study?

Register your interest

NCT06998303 | RECRUITING | Parkinson Disease


Imaging Core Aim 2, and Udall Project 2 Aim 2
Sponsor:

University of Minnesota

Brief Summary:

More than one million people in the United States have Parkinson's disease (PD) and the prevalence is expected to double by 2040. Over 60% of these individuals will develop debilitating postural instability and gait disturbances (PIGD), including freezing of gait (FOG). With disease progression, axial motor symptoms typically become resistant to dopamine replacement therapies (e.g. levodopa) and a primary source of disability and morbidity. While subthalamic (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) using standard locations and stimulation parameters can be highly effective for the treatment of the cardinalmotorsymptomsof PD, both treatments often fail to control levodopa-resistant motor features of PD such as PIGD. DBS can also impair cognitive function which further exacerbates PIGD, particularly when the task requires attentional resources. Thus, despite considerable improvements in appendicular bradykinesia, rigidity and tremor with conventional DBS, the disease can continue to be dominated by PIGD, leading to increased falls, decreased mobility, and increased rate of hospitalization and morbidity. This is why one of the top NINDS priorities for clinical research in PD is the development of novel therapeutic approaches, such as DBS targeting, to treat levodopa-resistant motor symptoms. This study will provide crucial information to elucidate the functional properties of the networks involved in Deep Brain Stimulation (DBS) treatment. By refining our understanding of the neural networks involved in stimulation of DBS targets, we will improve our ability to program patients to enhance their clinical outcomes and minimize side effects.

Condition or disease

Parkinson Disease

Intervention/treatment

Bipolar DBS stimulation

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 20 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Imaging Core Aim 2, and Udall Project 2 Aim 2
Actual Study Start Date : 2025-04-01
Estimated Primary Completion Date : 2026-07-31
Estimated Study Completion Date : 2026-07-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age 21 and up
  • * Implanted with MR-compatible DBS device (Medtronic Percept/Percept RC DBS System) for treatment of Parkinson's disease
  • * English speaking
Exclusion Criteria
  • * Unable to consent for themselves
  • * Implanted with a DBS device that is not MR compatible
  • * Pregnant
  • * Extreme claustrophobia
  • * Any contraindications for MRI

Imaging Core Aim 2, and Udall Project 2 Aim 2

Location Details

NCT06998303


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

United States, Minnesota

University of Minnesota

Minneapolis, Minnesota, United States, 55414

Loading...